| Alan B. Sachs |
Alan B. Sachs is currently the Chief Medical Officer at Thermo Fisher Scientific, Inc. He previously worked as the Director of Clinical Genomics at Merck & Co., Inc. and as a Director at Odyssey Thera, Inc. He also served as the Vice President of Basic Research at Sirna Therapeutics, Inc. for a brief period in 2011. Additionally, he held the position of Vice President of Molecular Profiling at Rosetta Inpharmatics LLC from 2002 to 2004. Prior to that, he was a Member at Massachusetts Institute of Technology from 1989 to 1992 and an Associate Professor at the University of California, Berkeley. He also worked as a Fellow at the Whitehead Institute for Biomedical Research. In 2002, he briefly served as the VP of Exploratory & Translational Sciences at Merck Research Laboratories Massachusetts LLC. He was also the Global Head of Research & Development at Life Technologies Corp. in 2012. Dr. Sachs obtained a doctorate degree from Stanford University and another doctorate degree from Stanford University School of Medicine. He completed his undergraduate studies at Cornell University. |
| Sebastian Pacios |
Sebastian Pacios is currently working as the Senior Vice President-Clinical Research at Thermo Fisher Scientific, Inc. He previously worked as the VP Operations-Europe, Asia Pacific & Africa at PRA International LLC from 2003 to 2007. Mr. Pacios holds a doctorate degree from Universidad Autónoma de Madrid. |
| Lisa P. Britt |
Lisa P. Britt is currently the Chief Human Resources Officer & Senior VP at Thermo Fisher Scientific, Inc. She previously worked as the Vice President-Human Resources at Covidien Unlimited Co. from 1998 to 2011 and as the Chief Human Resources Officer & Executive VP at Nexeo Solutions LLC from 2013 to 2017. Ms. Britt received her undergraduate degree from Lander University. |
| Michel Lagarde |
Michel Lagarde is currently an Independent Director at Vertex Pharmaceuticals, Inc., a Director at Populus Financial Group, Inc., a Director at American Dental Partners, Inc., a Director at Synarc-Biocore Topco Holdings, Inc., and the Chief Operating Officer & Executive Vice President at Thermo Fisher Scientific, Inc. He previously worked as the CEO & CFO-Domestic Appliances & Personal Care at Philips Electronics North America Corp., a Director at inVentiv Health Clinical, Inc., a Director at F C Holdings, Inc. (Texas), a Managing Director at JLL Partners, Inc., the Chief Financial Officer & Vice President at Philips Domestic Appliances & Personal Care North America, a Finance Controller at Philips Electronics Hong Kong Ltd., the Chief Financial Officer at PT Philips Electronics Indonesia, and the President & Chief Operating Officer at Patheon NV. Mr. Lagarde holds a graduate degree from Maastricht University, a graduate degree from the University of Amsterdam, and an undergraduate degree from the University of Antwerp. |
| Stephen Williamson |
Stephen Williamson is a Member of the Institute of Chartered Accountants in England & Wales. He is also currently serving as the Chief Financial Officer & Senior Vice President at Thermo Fisher Scientific, Inc. since 2015. Previously, he held the position of Independent Director at International Flavors & Fragrances, Inc. from 2017 to 2023. Prior to that, he was the Chief Financial Officer & VP-Asia Pacific at Honeywell Singapore Pte Ltd. from 1997 to 2001. Mr. Williamson completed his undergraduate degree at the University of Wales (Bangor) in 1988. |
| Karen E. Nelson |
Karen E. Nelson is currently the Chief Scientific Officer at Thermo Fisher Scientific, Inc. and a Member of the National Academy of Sciences. Previously, she served as the President & Trustee at J. Craig Venter Institute, Inc. from 2012 to 2021. Dr. Nelson holds a doctorate degree from Cornell University, a graduate degree from the University of Florida, and an undergraduate degree from The University of the West Indies. |
| Ryan Snyder |
Ryan Snyder is currently the Chief Information Officer & Senior Vice President at Thermo Fisher Scientific, Inc. He completed his undergraduate degree from State University of New York College at Geneseo in 1995 and his MBA from The University At Buffalo School of Management in 1998. |
| Joseph Holmes |
Joseph Holmes is currently the Chief Accounting Officer & Vice President at Thermo Fisher Scientific, Inc. He previously worked as the Director-Technical Accounting & Reporting at Abbott Laboratories in 2017 and at St. Jude Medical LLC from 2014 to 2017. |
| Aditya Joshi |
Aditya Joshi is currently the Chief Strategy Officer & Vice President at Thermo Fisher Scientific, Inc. He previously worked at Brain & Co. as a Partner. Mr. Joshi completed his undergraduate degree at Brown University and holds an MBA from Harvard Business School. |
| Mike Shafer |
Mike Shafer is currently the Senior VP & President-Pharma Services Group at Thermo Fisher Scientific, Inc. He previously worked as the Business Director-APAC at 3M Co. He completed his undergraduate degree at the University of Minnesota. |
| Cory Stevenson |
Cory Stevenson is currently the Executive Chairman at Gemini Bioproducts LLC and a Director at Gemini Bioproducts Holding, Inc. He also serves as an Advisor at BelHealth Investment Partners LLC. Previously, he held the position of President-Bioproduction Division at Thermo Fisher Scientific, Inc. Mr. Stevenson completed his undergraduate degree at the University of Utah and holds an MBA from Pepperdine University. |
| Michael J. Dubose |
Michael J. Dubose is an Independent Director at Watts Water Technologies, Inc. and a Director at The Health Industry Distributors Association. He is also the President-Fisher Healthcare Division at Thermo Fisher Scientific, Inc. His former positions include Vice President-Cross Border Business Globally at W.W. Grainger, Inc. and Regional Vice President at Staples, Inc. |
| Garret Hampton |
Garret Hampton is an Independent Director at IDEAYA Biosciences, Inc. and President-Clinical Sequencing & Oncology at Thermo Fisher Scientific, Inc. He was previously a Senior Director-Oncology Biomarker Development at Genentech, Inc. and Executive Vice President-Clinical Genomics at Illumina, Inc. He also worked as an Assistant Professor at the University of California San Diego. Hampton received his undergraduate and graduate degrees from Trinity College Dublin and his doctorate from University College London. |
| Marc N. Casper |
Marc N. Casper is currently the Chairman, President & Chief Executive Officer at Thermo Fisher Scientific, Inc. He is also an Independent Director at Synopsys, Inc. In addition, he holds director positions at The Brigham & Women's Hospital, Inc., Wesleyan University, Brigham & Women's Faulkner Hospital, Inc., Mass General Brigham, Inc., U.S. Bank NA (Boston MA), and The Business Roundtable. Mr. Casper is a Trustee at the US-China Business Council and the Massachusetts Math & Science Initiative. Formerly, Mr. Casper served as the President, Chief Executive Officer & Director at Kendro Laboratory Products LP. He was an Independent Director at U.S. Bancorp and Zimmer Biomet Holdings, Inc. He also held positions at Thermo Electron Corp., Analytical Technology, Inc., Dade Behring, Inc., and Bain Capital, Inc.Mr. Casper completed his undergraduate studies at Wesleyan University and earned an MBA from Harvard Business School. |
| C. Martin Harris |
C. Martin Harris founded VitalStream Health, Inc. in 2002. Dr. Harris also currently works at Colgate-Palmolive Co., as Independent Director from 2016, Agiliti Health, Inc., as Director, Thermo Fisher Scientific, Inc., as Independent Director from 2012, Agiliti, Inc. (Minnesota), as Director from 2022, MultiPlan Corp., as Independent Director from 2021, and Dell Medical School, as Chief Business Officer from 2016. Dr. Harris also formerly worked at Healthcare Information & Management Systems Society, as Chairman, National Health Information Infrastructure, as Chairman, Foundation for eHealth Initiative, as Chairman, The Cleveland Clinic Foundation, as Chairman-Information Technology Division from 2011 to 2016, Invacare Corp., as Lead Independent Director from 2015 to 2022, HealthStream, Inc., as Independent Director from 2010 to 2021, CareScience, Inc., as Director, Sentillion, Inc., as Director, e-Cleveland Clinic, as Executive Director from 2000 to 2016, Health Enterprises, Inc., as Associate Vice President, Cleveland Clinic Hospital, as Chief Information Officer, and the University of Texas at Austin Graduate School, as Professor-Internal Medicine. Dr. Harris received his undergraduate degree and doctorate degree from the University of Pennsylvania and Masters Business Admin degree from The Wharton School of the University of Pennsylvania. |
| Ruby R. Chandy |
Ruby R. Chandy is an Independent Director at Flowserve Corp., Thermo Fisher Scientific, Inc., DuPont de Nemours, Inc., and a Board Member at PPC Investment Partners LP. Previously, Ms. Chandy served as an Independent Director at AMETEK, Inc., Managing Director & VP-Dow Plastics Additives at The Dow Chemical Co., President-Industrial Division at Pall Corp., Chief Marketing Officer & Vice President at Rohm & Haas Co., President-Bioscience Technologies Division at Thermo Electron Corp., President-Microvasive Urology Division at Boston Scientific Corp., and Chief Marketing Officer & Vice President at Thermo Fisher Scientific, Inc. Ms. Chandy also worked as a Senior Associate at McKinsey & Co., Inc. Ms. Chandy holds an undergraduate degree and an MBA from Massachusetts Institute of Technology, as well as a graduate degree from Northwestern University. |
| Debora L. Spar |
Debora Spar is an Advisor to Xfund. She is the MBA Class of 1952 Professor of Business Administration and Senior Associate Dean at Harvard Business School where she teaches the first-year Strategy course. Her current research focuses on issues of gender and technology, and the interplay between technological change and broader social structures. Spar tackles some of these issues in her latest book The Virgin and the Plow: How Technology Shapes How we Live and Love.
Spar served as the President of Barnard College from 2008 to 2017, and as President and CEO of Lincoln Center for the Performing Arts from 2017 to 2018. During her tenure at Barnard, Spar led initiatives to highlight women’s leadership and advancement, including the creation of the Athena Center for Leadership Studies and the development of Barnard’s Global Symposium series.
Before joining Barnard, Spar spent 17 years on the Harvard Business School faculty as the Spangler Family Professor in the BGIE unit. She also served as Senior Associate Dean for Faculty Research and Development. During this period, her research primarily explored how political forces shape and constrain market behavior. She looked in particular at the politics of foreign trade and investment, and developed a second year course entitled Managing International Trade and Investment. Spar also studied the specific politics of reproductive science and tracked, in her 2006 book, The Baby Business, the emergence of a large (and largely unregulated) commercial market for fertility.
Spar is a member of the Academy of Arts and Sciences and serves as a director of Value Retail LLC and a trustee of the Howard Hughes Medical Institute. She has also served as a Director of Goldman Sachs and a trustee of the Markle and Wallace Foundations. Spar earned her Ph.D. in Government from Harvard University and her B.S. from Georgetown University’s School of Foreign Service. |
| James C. Mullen |
James C. Mullen is currently the Chief Executive Officer at DPx Holdings BV and the Non-Executive Chairman at Percivia LLC. He is also a Director at Thermo Fisher Scientific, Inc. Additionally, he is a Member at Biomedical Sciences Careers Program, Inc. and a Trustee at The Rivers School Corp. Previously, he served as the President, Chief Executive Officer & Director at Biogen, Inc. from 2003 to 2010. He was also the Chief Executive Officer & Executive Director at Patheon NV from 2011 to 2017. Furthermore, he was the Chairman at Biotechnology Innovation Organization. He has also served as an Independent Director at Revvity, Inc. and Insulet Corp. He was the President at Biogen Idec New Ventures, Inc. from 1989 to 2008. He holds an undergraduate degree from Rensselaer Polytechnic Institute and an MBA from Villanova University. Currently, he is the Executive Chairman at Editas Medicine, Inc. from 2022 to 2023 and was the Chairman at Torque Therapeutics, Inc. from 2018 to 2019. He is also the Executive Chairman at Vicarius Pharma AG. |
| Scott M. Sperling |
Scott M. Sperling is currently the Co-Chief Executive Officer at Thomas H. Lee Partners LP, Chairman at Mass General Brigham, Inc., an Independent Director at Agiliti, Inc. (Minnesota), a Director at Agiliti Health, Inc., a Director at iHeartMedia Capital I LLC, a Director at Partners HealthCare Corp., a Director at iHeartCommunications, Inc., a Director at Brigham & Women's, and the Lead Independent Director at Thermo Fisher Scientific, Inc. He is also the President of THL Portfolio Holdings Corp. In the past, Mr. Sperling served as the Executive Chairman of Federal Street Acquisition Corp., Chairman of The Wang Center For The Performing Arts, Inc., Director at Clear Channel Communications, Inc., Director at HM Publishing Corp., Director at Univision Communications, Inc., Director at Warner Music Group Corp., Director at Hawkeye Energy Holdings LLC, Director at Thomas H. Lee Advisors LLC, Director at Wyndham Hotels & Resorts LLC, Director at Livewire, Director at Tibbar LLC, Independent Director at MSG Networks, Inc., Director at Experian Information Solutions, Inc., Director at Pricellular Corp., Director at Fisher Scientific International, Inc., Director at Procurenet, Inc., Director at The Learning Co., Inc., Director at GenTek, Inc., Director at ProSiebenSat.1 Media SE, Director at Wyndham International, Inc., Director at Houghton Mifflin Holding Co., Inc., Independent Director at Madison Square Garden Sports Corp., Director at Aramark Services, Inc., Director at Vertis, Inc., Director at Front Line Management Group, Inc., Director at WMG Acquisition Corp., and Managing Partner at Aeneas Group, Inc.Mr. Sperling received his undergraduate degree from Purdue University and his MBA from Harvard Business School. |
| Lars Rebien Sørensen |
Lars Rebien Sørensen is currently the Chairman at Novo Nordisk Fonden, Chairman at Novo Holdings AS (Denmark), Chairman at Ferring Pharmaceuticals A, Vice Chairman at Ferring Holding SA, Chairman-Supervisory Board at Ferring International Center SA, and Independent Director at Thermo Fisher Scientific, Inc. He previously served as the President & Chief Executive Officer at Novo Nordisk A from 1982 to 2017, Chief Executive Officer at Novo Nordisk (Private Equity) from 2001 to 2014, Deputy Chairman-Supervisory Board at Carlsberg A from 2015 to 2019, Chairman-Supervisory Board at Carlsberg Breweries A from 2015 to 2019, Director at ZymoGenetics, Inc. from 1996 to 2010, and Independent Director at Thermo Fisher Scientific, Inc. from 2011 to 2015. He has also held positions as a Director at Svenska Cellulosa AB SCA, Director at Danmarks Nationalbank, Director at Ørsted A, Director at Cameron Services AG, Independent Director at Thermo Fisher Scientific, Inc., Independent Director at Essity AB, Member-Supervisory Board at Bertelsmann SE & Co. KGaA, Professor at the University of Copenhagen, Member-Supervisory Board at Bertelsmann Management SE, and Member-Supervisory Board at Essity Germany GmbH. Mr. Sørensen obtained his undergraduate degree from Copenhagen Business School in 1983 and his graduate degree from the University of Copenhagen in 1981. |
| Dion J. Weisler |
Dion J. Weisler is currently serving as an Independent Director at Intel Corp., BHP Group Ltd., BHP Group (UK) Ltd., and Thermo Fisher Scientific, Inc. He is also a Director at Technology CEO Council and a Non-executive Director at Sapia & Co. Pty Ltd. In the past, he served as the President & CEO of HP Tech Ventures and as a Director at HP, Inc. He also held positions at Acer U.K. Ltd., Telstra Corp. Ltd., and Lenovo Group Ltd. He completed his undergraduate degree from Monash University. |
| R. Alexandra Keith |
R. Alexandra Keith is currently the Chief Executive Officer-Beauty at Procter & Gamble Co. and the Chief Executive Officer at Beauty, Inc. She is also an Independent Director at Thermo Fisher Scientific, Inc. In addition, she holds positions as a Director at Personal Care Products Council and as a Director & Member at Cosmetic Executive Women, Inc. Previously, Ms. Keith served as the Director at the National Underground Railroad Freedom Center, Inc. from 2012 to 2016. She also held the position of Director at Cincinnati Ballet. Additionally, she was the Director at the American Cleaning Institute from 2012 to 2014 and the Director at Go Vibrant from 2011 to 2014. Furthermore, she served as the Director at Gotr Cincinnati from 2008 to 2015. Ms. Keith obtained her undergraduate degree from the University of Arizona in 1989. |
| Tyler E. Jacks |
Tyler E. Jacks is the founder of T2 Biosystems, Inc. (founded in 2006) and Dragonfly Therapeutics, Inc. (founded in 2016). He currently holds positions as an Independent Director at Amgen, Inc. (since 2012), Director at Thermo Fisher Scientific, Inc. (since 2009), President & Director at Commonwealth Cancer Consortium, Inc. (since 2021), and Professor at Massachusetts Institute of Technology (since 2007). Dr. Jacks previously served as Chairman at the National Cancer Institute and as Director at the David H. Koch Institute for Integrative Cancer Research (from 2007 to 2021). He received his undergraduate degree from Harvard University in 1983 and his doctorate degree from The University of California, San Francisco in 1988. |
| Nelson J. Chai |
Nelson J. Chai is currently the Director-School of Arts & Sciences at the University of Pennsylvania, Independent Director at Thermo Fisher Scientific, Inc., Director at The College of Arts & Sciences, and President at Virginia Surety Co., Inc. Previously, he served as the President & Chief Executive Officer of The Warranty Group, Inc. and The Warranty Group, Inc. (Investment Portfolio), Chairman of CIT Bank NA, Vice Chairman of CIT Bank (Utah), Director at United Nations Children's Fund and United States Fund for UNICEF, Co-President of CIT Group, Inc., Chief Financial Officer & Executive Vice President of Merrill Lynch & Co., Inc., President-Asia Pacific Region at Bank of America Corp., Senior VP-Business Development & Controller at Dade Behring Holdings, Inc., Chief Financial Officer & Executive Vice President of NYSE Group, Inc., Chief Financial Officer of Archipelago Holdings, Inc., and Chief Financial Officer & Executive Vice President of NYSE Euronext, Inc. He is currently the Chief Financial Officer at Uber Technologies, Inc. Mr. Chai received his undergraduate degree from the University of Pennsylvania and his MBA from Harvard Business School. |
